Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
The Primary Care Companion for CNS Disorders|October 31, 2013
Association between severity of depression and self-perceived cognitive difficulties among full-time employeesCarol Lawrence, Anuja Roy, Venkatesh Harikrishnan, et al.
Expert Opinion on Pharmacotherapy|August 10, 2007
Comparative economic analysis of aromatase inhibitors and tamoxifen in the treatment of hormone-dependent breast cancerLesley-Ann N Miller, Anuja Roy, Reema Mody, et al.
Journal of Occupational and Environmental Medicine|February 27, 2013
Patient-reported depression severity measured by the PHQ-9 and impact on work productivity: results from a survey of full-time employees in the United StatesGagan Jain, Anuja Roy, Venkatesh Harikrishnan, et al.
Applied Health Economics and Health Policy|August 24, 2016
Panobinostat Plus Bortezomib Versus Lenalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Treatment Comparison of Survival Outcomes using Patient-level DataIstvan Majer, Gijs van de Wetering, Zoltan Polanyi, et al.
Clinicoeconomics and Outcomes Research : CEOR|November 23, 2018
Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopeniaGabriel Tremblay, Mike Dolph, Menaka Bhor, et al.
British Journal of Haematology|December 29, 2018
Health-related quality of life in children with chronic immune thrombocytopenia treated with eltrombopag in the PETIT studyJohn D Grainger, Victor S Blanchette, Kelly M Grotzinger, et al.
Annals of Hematology|July 18, 2022
Thrombopoietin receptor agonist discontinuation rates and reasons among patients with immune thrombocytopenia: a study of administrative claims linked with medical chart reviewAdam Cuker, Lincy Lal, Anuja Roy, et al.
Expert Review of Hematology|September 9, 2017
Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agentPaul Richardson, Anuja Roy, Suddhasatta Acharyya, et al.
Journal of Comparative Effectiveness Research|June 1, 2018
A decision framework for treating chronic immune thrombocytopenia with thrombopoietin receptor agonistsMike Dolph, Anuja Roy, Menaka Bhor, et al.
Journal of Managed Care & Specialty Pharmacy|June 23, 2022
Baseline characteristics and secondary medication adherence among Medicare patients diagnosed with transthyretin amyloid cardiomyopathy and/or receiving tafamidis prescriptions: A retrospective analysis of a Medicare cohortAnuja Roy, Andrew Peterson, Nick Marchant, et al.
Pageof 3